Intradialytic Blood Pressure Abnormalities: The Highs, The Lows and All That Lies Between

Magdalene M. Assimon a, b Jennifer E. Flythe a, c

a University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, b Department of Epidemiology, UNC Gillings School of Global Public Health, and c Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, N.C., USA

Key Words
Blood pressure · Hemodialysis · Intradialytic hypotension · Intradialytic hypertension · Blood pressure variability

Abstract
Background: Frequent blood pressure (BP) measurements are necessary to ensure patient safety during hemodialysis treatments. Intradialytic BPs are not optimal tools for hypertension diagnosis and cardiovascular risk stratification, but they do have critical clinical and prognostic significance. We present evidence associating intradialytic BP phenomena including fall, rise and variability with adverse clinical outcomes and review related pathophysiologic mechanisms and potential management strategies. Summary: Observational studies demonstrate associations between intradialytic hypotension, hypertension and BP variability and mortality. Lack of consensus regarding diagnostic criteria has hampered data synthesis, and prospective studies investigating optimal management strategies for BP phenomena are lacking. Mechanistic data suggest that cardiac, gut, kidney and brain ischemia may lie on the causal pathway between intradialytic hypotension and mortality, and endothelial cell dysfunction, among other factors, may be an important mediator of intradialytic hypertension and adverse outcomes. These plausible pathophysiologic links present potential therapeutic targets for future inquiry. The phenomenon of intradialytic BP variability has not been adequately studied, and practical clinical measures and treatment strategies are lacking. Key Messages: Intradialytic BP phenomena have important prognostic bearing. Clinical practice guidelines for both intradialytic hypotension and hypertension exist, but their underlying evidence is weak overall. Further research is needed to develop consensus diagnostic criteria for intradialytic hypotension, hypertension and BP variability and to elucidate optimal treatment and prevention strategies for each BP manifestation.

Introduction

Blood pressure (BP) measurement is a fundamental part of hemodialysis (HD) administration with measurements taken before and after HD and at frequent intervals during the treatment. It is well recognized that these peridialytic and intradialytic BP measurements are poorly reflective of interdialytic BP behavior and overall cardiovascular disease burden [1−3]. However, such BP measurements are essential for monitoring patient safety during
dialysis. Peridialytic BPs and adverse clinical outcomes have a well-described ‘U’-shaped association [4, 5], but no prospective studies have established optimal intervention thresholds on either end of the BP spectrum. Overt intradialytic BP abnormalities such as hypotension in a pale, diaphoretic patient or hypertension in a patient with headache and vision change are impossible to ignore. Such drastic presentations spark immediate intervention, and elegant studies demonstrating harm are not needed. While these extreme BP events occur more often than desired, they are relatively infrequent in today’s era of bicarbonate-based dialysate and volumetric ultrafiltration (UF).

Instead, the clinical dilemmas and prognostic uncertainties lie along a spectrum of seemingly minor and often asymptomatic intradialytic BP falls, elevations and fluctuations. Such uncertainties stem from lack of consensus definitions for intradialytic hypotension, hypertension and BP variability and the paucity of evidence on effective intervention and prevention strategies. These evidence limitations combined with absence of associated symptoms contribute to the tendency to conflate asymptomatic BP fluctuations with ‘normal’ BP. However, growing evidence suggests harm from aberrant, asymptomatic intradialytic BP changes. Currently, a hierarchy exists with regards to the volume and quality of existing literature. Intradialytic hypotension has both the largest and strongest clinical evidence base, followed by intradialytic hypertension and intradialytic BP variability, respectively. Herein, we review evidence associating different intradialytic BP phenomena, including BP fall, rise and variability, with adverse clinical outcomes, summarize their pathophysiology and management, and identify uncertainties requiring further research.

**Dialysis Unit BP Measurements**

Clinicians have a plethora of BP measurements available when caring for in-center, thrice-weekly, maintenance HD patients. The most abundant measurements are peridialytic BPs, measurements taken before and after HD, and intradialytic BPs, measurements assessed at frequent intervals during HD. Despite their accessibility, peridialytic and intradialytic BPs are limited in their diagnostic capacity. Ambulatory and home BP measurements are more reliable for diagnosing hypertension and performing cardiovascular risk stratification than peridialytic BPs [2, 6, 7]. Technical, patient and HD procedural factors thwart in-center BP diagnostic accuracy. In a study comparing BP measurement techniques, Rahman et al. [8] demonstrated BP overestimation with HD machine-automated measurements compared to BPs taken by a sphygmomanometer operated in accordance with American Heart Association guidelines. Numerous potential sources for error in machine-measured BPs exist. First, equipment error introduced by incorrectly sized cuffs or out-of-date BP machine validation and calibration may contribute to inaccuracies [9]. Second, patient position and recent activities including caffeine ingestion, exercise and smoking may impact measurements. Third, factors related to the dialysis vascular access and underlying vascular disease are also salient. While BP is typically taken in the arm opposite to the access, lower extremity BPs are measured when brachial measurements are not possible. Peripheral amplification of pulse pressure and poorly sized cuffs lead to higher BP readings in the lower extremities [9]. These potential measurement errors complicate not only chairside, clinical BP interpretation, but also create potential inaccuracies in research utilizing routinely measured dialysis unit BPs.

Even in studies where BP measurement technique is standardized and patient differences are accounted for, in-center BP readings do not correlate well with ambulatory BPs [10]. Factors unique to the dialytic period including fluid and osmolar shifts and erythropoietin stimulating agents (ESAs) affect cardiac output and BP. These dynamic conditions combined with high potential for measurement error limit the diagnostic capacity of in-center BPs. Despite these limitations, in-center BP measurements do have substantial clinical and prognostic importance, particularly with regard to identifying dynamic BP changes as we review in the following sections.

**Intradialytic BP Patterns**

Observational studies of intradialytic BP patterns have identified extremes of BP fall, rise and fluctuations as important prognostic indicators. Pre- to post-dialysis BP change has been demonstrated to have a J- or U-shaped mortality association in epidemiologic studies [4, 5]. In a recent analysis of over 110,000 patients, Park et al. [5] reported a U-shaped association between mean pre- to post-HD systolic BP change and mortality. Authors found that peak survival was observed in patients with BP fall of 14 mm Hg during HD. Patients with intradialytic BP falls >30 mm Hg or BP rise >0 mm Hg had greater mortality. In analyses stratified by pre-HD systolic BP, U-shaped associations between BP change and outcomes were found only in pre-HD systolic BP categories.
≥120 mm Hg. Pre- to post-HD BP change has an important limitation as a prognostic metric, because it does not reflect individual intradialytic BP measurements such as nadir systolic BP. The measure thus falls short in accurately capturing intradialytic BP fluctuations of known clinical importance. Such intradialytic BP fluctuations are common. BP behavior during HD is influenced by a variety of physiologic and procedural factors including UF-driven fluid shifts, serum osmolality changes, neurohormonal axis and inflammatory pathway activation and dialytic removal of antihypertensives and other vasoactive substances. High burdens of comorbid disease and non-traditional cardiovascular risk factors such as stiff vasculature, impaired vasoreactivity and autonomic dysfunction render dialysis patients particularly vulnerable to hemodynamic compromise from BP fluctuations.

In a study of intradialytic BPs in 218 patients across >2,000 HD treatments, Dinesh et al. [11] characterized the intradialytic temporal trend of systolic BP behavior with a 2-slope linear spline. The model describes the following: (1) systolic BP at HD start, (2) a rapid decrease in systolic BP during the first 25% of treatment (slope of \(-25.5 \pm 1.5 \text{ mm Hg}\)) and then (3) a more gradual decline in systolic BP in the latter 75% of treatment (slope of \(-5.8 \pm 0.5 \text{ mm Hg}\)). Higher UF volume and rate and calcium acetate use were associated with greater pre-HD BP and a more rapid decline in both early- and late-HD BP slopes. Departures from this expected BP course include precipitous BP drops (intradialytic hypotension), pre- to post-dialysis BP elevation (intradialytic hypertension) and more subtle BP fluctuations (intradialytic BP variability) as shown in figure 1. All 3 BP phenomena are associated with adverse clinical outcomes.

**Intradialytic BP Fall**

**Epidemiology and Definitions**

Intradialytic hypotension is a well-recognized HD complication, occurring in 10–70% of treatments, depending on the definition [12]. Patient and clinical characteristics associated with intradialytic hypotension include older age, female sex, longer dialysis vintage, diabetes, lower pre-dialysis BP, lower albumin and higher body mass index [12, 13]. Low BP during HD has been associated with a range of clinical and pathogenic consequences including inadequate dialysis dose, myocardial stunning, brain atrophy, vascular access thrombosis and increased mortality [12, 14–17]. Surprisingly, we lack the diagnostic criteria for intradialytic hypotension and consensus on optimal intervention thresholds.

Most clinical practice guidelines require the presence of symptoms or administration of interventions to fulfill intradialytic hypotension diagnostic criteria, but many epidemiologic studies associating hypotension with adverse outcomes are based on BP values alone. The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) and European Best Practices Guidelines define intradialytic hypotension as a decrease in systolic BP ≥20 mm Hg or a drop in mean arterial pressure (MAP) ≥10 mm Hg during HD with associated symptoms [18, 19]. In the Hemodialysis Study (HEMO Study), intradialytic hypotension was defined as hypotension requiring either saline infusion or UF rate or blood flow reduction. Administrative research databases typically lack symptom and complete intervention data, necessitating definitions utilizing BP values alone. Such definitions are based on requisite BP falls (10–40 mm Hg) or
nadir intradialytic BP thresholds (60–100 mm Hg) [20–23]. Other definition formulations combine requisite drops or thresholds with the presence of symptoms and/or interventions. For example, Chesterton et al. [24] defined intradialytic hypotension with a nadir systolic BP <100 mm Hg or a >10% intradialytic BP fall plus the presence of symptoms. Unfortunately, definition discrepancies have limited data synthesis and hindered the development of evidence-based management guidelines.

Recently, Flythe et al. [12] aimed to address the lack of uniform intradialytic hypotension diagnostic criteria by examining associations between commonly used definitions and mortality. This study clearly illustrates the influence of hypotension definition on prevalence estimates. Intradialytic hypotension defined as systolic BP fall >20 mm Hg was observed in 68% of treatments during the exposure period. In contrast, hypotension defined as systolic BP fall below 90 mm Hg was present in only ~10% of the exposure treatments. When outcomes were considered, nadir systolic BP of 90 mm Hg was associated with greater all-cause mortality, adjusted odds ratio (95% CI), 1.56 (1.05–2.31) in the HEMO Study cohort and 1.30 (1.07–1.57) in the large dialysis organization cohort. Other intradialytic hypotension definitions were not associated with mortality. Neither addition of symptoms nor interventions to nadir-based definitions strengthened their associations with mortality. This finding stands in contrast to the existing clinical guideline intradialytic hypotension definitions that require symptoms or interventions [18, 19]. In a recent prospective study, Meredith et al. [25] demonstrated poor correlation between symptoms and nursing interventions for hypotension, further underscoring potential inaccuracy associated with symptom-based definitions. Overall, existing data suggest that a nadir-based intradialytic hypotension definition may be optimal for capturing mortality risk.

Pathophysiology

Maintenance of adequate blood volume during dialysis is dependent on multiple patient and HD factors. In absence of serious medical conditions such as infection, arrhythmias, pericardial tamponade, myocardial infarction and hemorrhage and HD complications such as hemolysis, air embolism and dialyzer reactions, intradialytic hypotension ensues when the pace of fluid removal exceeds the pace of plasma refill and associated physiologic compensatory responses. Decreased effective arterial blood volume during overly aggressive UF leads to decreased cardiac filling, decrements in cardiac output and, ultimately, hypotension. There are numerous patient, cardiovascular, volume and HD treatment-related risk factors for intradialytic hypotension (fig. 2a). Compensatory mechanisms include increased cardiac output, enhanced plasma refill, passive venoconstriction and increases in arterial tone. Cardiac output is augmented by increased contractility and, to a lesser extent, increased heart rate [26]. The pathophysiologic mechanisms underlying intradialytic hypotension provide insight into potential management strategies. Dialysate sodium, plasma albumin and the magnitude of hydrostatic capillary force all influence plasma refill. Exposure to higher dialysate–serum sodium gradients increases fluid mobilization into the intravascular space. Similarly, higher plasma osmolality, associated with greater albumin levels, enhances refill. Intradialytic osmolality decline from uremic toxin removal and sodium gradient equilibration lead to slowed vascular refill over the treatment course. Procedural factors such as warm dialysate, acetate buffer or eating during dialysis increase the risk of hypotension by decreasing peripheral resistance. Autonomic dysfunction and impaired baroreceptor sensitivity dampen the compensatory cardiac responses to these blood volume reductions [27]. Cardiac abnormalities such as diastolic dysfunction, atrial fibrillation, left ventricular hypertrophy and ischemic heart disease also contribute. When compensatory responses for reduced cardiac filling reach their limits, BP falls [26].

Furthermore, emerging data suggest that episodes of intradialytic hypotension beget future hemodynamic instability. Intradialytic hemodynamic compromise has been linked to episodic stunning of the myocardium [14, 15]. Over time, repeat ischemia induces cardiac hypertrophy and fibrosis, further impairing response to decreased filling pressures and increasing risk for hemodynamic instability. Related, intradialytic gut hypoperfusion may increase systemic endotoxin levels. Endotoxemia is linked to chronic inflammation and cardiovascular risk via potentiation of pro-inflammatory cytokine generation, oxidative stress and endothelial dysfunction [28]. Finally, hypoperfusion injury to the kidney may accelerate the loss of native kidney function among patients with residual kidney function, an independent risk factor for mortality [29].

Outcome Associations

Table 1 summarizes representative studies of intradialytic hypotension and mortality. While intradialytic hypotension is frequently cited as a mortality risk factor, observational studies have yielded mixed results. A 2003 Hungarian study found no association between intradia-
lytic hypotension and mortality [30]. In contrast, a 2004 Japanese analysis demonstrated an association between intradialytic hypotension and greater mortality with lower nadir systolic BP associating with higher all-cause death risk [31]. In 2014, Stefánsson et al. [32] examined the relationship between intradialytic hypotension and all-cause mortality and a composite outcome of myocardial infarction, stroke and cardiovascular mortality in a US cohort, finding associations with both. These discrepant findings may, in part, be explained by differences in hypotension definitions and number of HD treatments used to identify hypotensive episodes. The Japanese study considered only one HD treatment, whereas the Hungarian and US analyses classified intradialytic hypotension over longer periods, 10 months and 90 days, respectively. In a 2 cohort observational analysis, Flythe et al. [12] demonstrated an association between intradialytic nadir systolic BP <90 mm Hg and all-cause mortality. These findings were robust in both cohorts and across varying levels of pre-HD systolic BP. Beyond mortality, intradialytic hypotension has been associated with vascular access thrombosis and mesenteric ischemia [16, 22].

Studies considering the associations of BP fall and intermediate outcomes link hemodynamic insults to a range of adverse end-organ sequelae including cardiac ischemia, gut ischemia and structural brain changes. In 2
studies Burton et al. [15, 33] describe greater intradialytic BP fall among patients with cardiac ischemia as evidenced by myocardial wall stunning on echocardiography. However, simultaneous assessments of BP and echocardiography limit causality inferences. Troponin elevations over the course of dialysis further supports HD treatment-associated cardiac ischemia [34]. Furthermore, hypotension has been linked to gut ischemia. Interruptions to bowel perfusion can result in endotoxin translocation to the bloodstream. A study by McIntyre et al. [28] reported elevated blood endotoxin levels among HD patients with greater intradialytic BP fall. Additionally, hypoperfusion-induced brain injury among HD patients may also contribute to adverse outcomes [17]. Firm conclusions about the associations of and causal pathways between intradialytic hypotension and these intermediate outcomes are limited by the use of cross-sectional study designs, small sample sizes and potential residual confounding from factors such as low pre-HD BP, diabetes, comorbid cardiac disease and hypoalbuminemia not accounted for in these descriptive studies. Despite their limitations, these mechanistic investigations provide compelling evidence supporting associations of intradialytic hemodynamic instability and intermediate, non-fatal outcomes including hypoperfusion-induced heart, gut and brain insults.

**Management**

Frank symptomatic intradialytic hypotension mandates swift nursing intervention. Acute management may include stopping UF or HD entirely, placing the patient in the Trendelenburg position and/or administering intravenous fluid and supplemental oxygen. Intervention selection is typically driven by event severity and is left to clinical judgment. Evidence supporting BP thresholds for intervention and optimal approaches for BP restoration are limited. For intravascular volume repletion, most clinicians rely on isotonic saline but options include hypertonic saline, hypertonic glucose, 5% dextrose and albumin. Use of albumin is expensive, and a small randomized trial suggested equivalence between saline and

### Table 1. Studies of intradialytic hypotension and mortality associations among HD patients

<table>
<thead>
<tr>
<th>Reference, year</th>
<th>n (country)</th>
<th>Exposure(s)</th>
<th>Outcome(s)</th>
<th>Major findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tislér et al. [30], 2003</td>
<td>263 (Hungary)</td>
<td>Nadir systolic BP ≤90 mm Hg or systolic BP fall ≥30 mm Hg plus the presence of associated symptoms and an intervention present in ≥10 HD treatments in a 10-month period</td>
<td>All-cause mortality</td>
<td>• Frequent intradialytic hypotension was not associated with all-cause mortality</td>
</tr>
<tr>
<td>Shoji et al. [31], 2004</td>
<td>1,206 (Japan)</td>
<td>Intradialytic systolic BP fall ≥40 mm Hg in a single baseline HD session</td>
<td>2-year all-cause mortality</td>
<td>• Intradialytic hypotension was associated with ↑ mortality across all pre-HD BP strata ♦ Nadir systolic BP was associated with ↑ mortality</td>
</tr>
<tr>
<td>Stefánsson et al. [32], 2014</td>
<td>39,497 (US)</td>
<td>Intradialytic systolic BP fall ≥20 mm Hg and ≥2 of the following: UF rate reduction, blood flow reduction, saline administration or premature cessation of HD present in ≥1 HD treatment in a 90-day period</td>
<td>All-cause mortality Cardiovascular composite event (myocardial infarction, stroke, cardiovascular mortality)</td>
<td>• Intradialytic hypotension was associated with ↑ mortality ♦ Intradialytic hypotension was associated with an ↑ in cardiovascular composite event</td>
</tr>
<tr>
<td>Flythe et al. [12], 2015</td>
<td>1,409 (US)</td>
<td>• HEMO Study cohort: intradialytic nadir systolic BP &lt;90 mm Hg present in ≥30% of HD treatments in the pre-randomization period plus 4 months (7–11 treatments) ♦ Large dialysis organization cohort: intradialytic nadir systolic BP &lt;90 mm Hg present in ≥30% of HD treatments in a 30-day period (12–15 treatments) ♦ Other intradialytic hypotension definitions: intradialytic systolic BP fall ≥20 mm Hg and ≥30 mm Hg (separately); nadir intradialytic systolic BP &lt;100 mm Hg; combinations of fall and nadir definitions; definitions with symptom or intervention requirements</td>
<td>All-cause mortality</td>
<td>• Intradialytic hypotension was associated with ↑ mortality in both study cohorts ♦ Frequency of intradialytic hypotension was associated with an incremental ↑ in mortality ♦ Other definitions were not associated with mortality ♦ Addition of symptoms or interventions to a nadir systolic BP &lt;90 mm Hg definition did not augment the mortality association</td>
</tr>
</tbody>
</table>

Downloaded by: 54.70.40.11 - 11/20/2017 10:22:41 AM
Hypertonic glucose may be the most effective at restoring blood volume, but use is limited by the high diabetes prevalence among HD patients [36]. Once hemodynamic stability is restored, attention turns to ruling out causative procedural complications such as hemolysis, air embolus and dialyzer reactions. Non-procedural causes such as pericardial tamponade, cardiac ischemia, hemorrhage and infection should be assessed via history and examination. In cases where BP is not responsive to interventions or when hypotension is accompanied by chest or abdominal pain, dyspnea or fever, patients may require hospital evaluation for cardiac ischemia, sepsis and occult bleeding.

While restoration of the circulatory volume is the priority during episodes of intradialytic hypotension, downstream consequences of interventions such as fluid administration, target weight adjustment and dialysate sodium adjustment should not be discounted. First, patients with frequent hypotension are at risk for recurrent target weight misses and chronic volume overload. Both of these clinical scenarios are associated with mortality [37, 38]. Clinical experience reveals that target weights are often adjusted upward to ‘match’ achieved post-weights following hypotension. In these cases, clinicians assume the target weight is underestimated. While target weight adjustment is occasionally required, it is the authors’ opinion that weight change should not be the default response to hypotensive episodes [39]. Hypotensive events often reflect a mismatch in UF and refill rates rather than total body volume depletion. Unfortunately, we lack objective measures to help distinguish these situations. Clinical clues such as the intradialytic timing of the hypotensive event and tools such as blood volume monitors may be helpful [40]. Hypotension early in HD may reflect pre-existing hypovolemia and should prompt reassessment of target weight, while late treatment hypotension may represent either an excessive UF rate or target weight over-estimation. Other precipitants also remain plausible. Second, hypertonic saline administration (and to a lesser extent, isotonic saline) and use of wide dialysate-serum sodium gradients lead to sodium loading, a risk factor for interdialytic thirst and subsequent interdialytic weight gain (IDWG) [41, 42]. Greater IDWG is associated with more frequent intradialytic hypotension and greater cardiovascular morbidity and mortality [43]. Related, sodium modeling, an effective hypotension preventive maneuver, has been rendered obsolete due to associated sodium loading [41]. Ultimately, clinicians must balance the risk of future hypotensive events against the risk of volume overload.

**Table 2.** Clinical guidelines for intradialytic hypotension prevention [19]

<table>
<thead>
<tr>
<th><strong>First-line</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dietary counseling (sodium restriction)</td>
</tr>
<tr>
<td>Avoidance of food ingestion during dialysis</td>
</tr>
<tr>
<td>Clinical reassessment of target weight</td>
</tr>
<tr>
<td>Use of bicarbonate dialysis buffer</td>
</tr>
<tr>
<td>Use of dialysate temperature of 36.5°C</td>
</tr>
<tr>
<td>Review of dosing and timing of antihypertensives</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Second-line</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective measures for reassessment of target weight</td>
</tr>
<tr>
<td>Cardiac evaluation</td>
</tr>
<tr>
<td>Gradual reduction of dialysate temperature (lowest 35°C)</td>
</tr>
<tr>
<td>Individualized blood volume controlled feedback</td>
</tr>
<tr>
<td>Increased dialysis treatment time or extra treatment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Third-line</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Midodrine</td>
</tr>
<tr>
<td>L-Carnitine supplementation</td>
</tr>
<tr>
<td>Dialysis modality change</td>
</tr>
</tbody>
</table>

Acute hypotensive episodes should be contextualized in the patient’s recent clinical history. Data demonstrate a dose–response association between intradialytic hypotension and mortality; more frequent hypotension is associated with an incrementally greater risk of death [12]. Preventive strategies should be considered in patients with recurrent hypotension. The European Best Practice Guidelines for intradialytic hypotension prevention are presented in table 2 [19]. Preventative strategies should be accompanied by a medication review with focus on dosing and timing of antihypertensives, opiates and other sedating medications. Evaluation for underlying ischemic heart disease and heart failure may be indicated.

Definitive, evidence-based intradialytic hypotension prevention strategies are few. Dialysate cooling has the best efficacy data with randomized trial data showing decreased brain white matter changes with cooled dialysate and a systematic review of 22 studies finding clinical benefit to cooled dialysate [44, 45]. However, formal assessments of patient tolerance and preference are lacking. Dialysis treatment time extension or additional HD treatments to facilitate more gradual fluid removal are helpful for some patients, but implementation of these strategies are limited by patient acceptance [46]. Additional HD treatment-related hypotensive preventive strategies include the following: UF modeling, the practice of varying the UF rate during HD, and sequential dialysis, the practice of isolated UF followed by UF plus HD. Both prac-
In patients with recurrent hypotension despite preventative measures, addition of midodrine, a selective alpha-1 adrenergic agonist, may be considered. A systematic review of 10 studies and 117 patients found that compared with control, midodrine was associated with increased nadir and post-HD systolic BPs [48]. Midodrine is typically dosed 15–30 minutes before dialysis but dosing may be split into pre-HD and mid-HD doses to help mitigate late treatment hypotension. Vigilance for side effects including urinary retention, supine hypotension and pruritus is warranted [48]. The supplement, L-carnitine, has not proven effective in preventing intradialytic hypotension [49]. Less well-studied preventative medications include sertraline and vasopressin [50, 51]. Among patients with refractory, recurrent hypotensive episodes, change to peritoneal, nocturnal or daily dialysis may be warranted.

**Intradialytic BP Rise**

**Epidemiology and Definitions**

While less common than intradialytic hypotension, intradialytic hypertension is another BP phenomenon with important prognostic significance. Patient and clinical characteristics associated with intradialytic BP rise include older age, lower body weight, lower serum creatinine and albumin and utilization of more antihypertensive medications [52, 53]. The prevalence of intradialytic hypertension is in the range of 5–15% among maintenance HD patients, depending on the definition [54, 55]. Currently, there is no universally accepted definition of intradialytic hypertension. It is typically defined as BP increase during or immediately after HD, resulting in post-HD BP >130/80 mm Hg, the KDOQI hypertension threshold [54]. Clinical investigations of this BP abnormality have used a range of definitions with varied thresholds of systolic BP or MAP increase (≥10 or 15 mm Hg) [52]. Others have selected more general definitions such as hypertension late in dialysis after the occurrence of the majority of UF or BP rise resistant to UF [56]. Some definitions are limited to subpopulations such as patients with de novo hypertension with ESA initiation, thereby narrowing generalizability [57].

**Pathophysiology**

The pathophysiology underlying paradoxical intradialytic BP rise is not fully understood, but data suggest interplay among positive sodium balance, volume overload, activation of the renin–angiotensin–aldosterone system (RAAS) and sympathetic nervous system, hemodialytic removal of antihypertensives, endothelial cell dysfunction, ESAs and bone mineral disease axis abnormalities (fig. 2b). Hypervolemia is a well-recognized risk factor for hypertension among HD patients and is the cause of intradialytic hypertension in a subset of patients [58, 59]. In one study, additional UF reduced cardiac dilation on echocardiography and lowered cardiac index and MAP [58]. However, factors beyond volume overload are important mediators of intradialytic hypertension in many patients.

Sympathetic nervous system overactivity, RAAS activation and associated vasoconstriction are plausible contributors. However, patients with intradialytic hypertension experience an intradialytic rise in systemic vascular resistance without a consistent, concurrent increase in catecholamine or renin levels, signifying that other mechanisms may drive the development of intradialytic hypertension [60]. In addition, other contributors to intradialytic hypertension include hemodialytic removal of antihypertensive medications (e.g., atenolol, metoprolol and angiotensin converting enzyme (ACE) inhibitors) and a positive calcium balance conferred from higher dialysate calcium concentrations [54].

Recent investigations have established endothelial cell dysfunction as a key mediator in intradialytic hypertension. Endothelial cells contribute to BP homeostasis by synthesizing and releasing humoral factors such as nitric oxide, a smooth muscle vasodilator and endothelin-1, a vasoconstrictor. Among patients with intradialytic hypertension, studies have demonstrated that endothelin-1 levels rise during dialysis while systemic nitric oxide levels remain inappropriately low [60, 61]. ESA may contribute to intradialytic hypertension via this mechanism [62]. The role of impaired endothelial cell response to HD is further supported by studies demonstrating a decrease in intradialytic hypertension frequency in response to the beta blocker carvedilol, a medication that suppresses endothelin-1 release in vitro [63]. Additionally, greater dialysate sodium may contribute to intradialytic hypertension through 2 mechanisms: enhanced
IDWG and stimulated release of endothelial-derived vasoregulators. A small crossover trial demonstrated lower mean BPs with use of lower dialysate sodium but no change in intradialytic endothelin-1 or nitric oxide levels. Authors postulated that carryover effects from the study arms may have inhibited detection of changes in vasoregulators [64].

**Outcome Associations**
Paradoxical intradialytic BP rise has been noted for decades, but its association with cardiovascular morbidity and mortality has only recently been recognized. Table 3 provides an overview of studies investigating intradialytic hypertension and mortality associations. In a post-hoc analysis of the Crit-line Intradialytic Monitoring Benefit Study (CLIMB Study), Inrig et al. [52] found that patients whose BP rose or failed to lower with HD had a twice the odds of non-vascular access-related hospitalization or death at 6 months compared to patients with pre- to post-HD BP fall. In an incident HD cohort, Inrig et al. [53] found that every 10 mm Hg rise in pre- to post-HD systolic BP was associated with a 12% ↑ in mortality risk.

<table>
<thead>
<tr>
<th>Reference, year</th>
<th>Study, n (country)</th>
<th>Exposure(s)</th>
<th>Main outcome(s)</th>
<th>Major findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inrig et al. [52], 2007</td>
<td>443 (US; Canada)</td>
<td>• Intradialytic hypertension was not explicitly defined, but a mean rise in pre- to post-systolic BP ≥10 mm Hg was assessed • Mean systolic BP values were computed from readings in 4 HD treatments occurring in the pre-intervention period and the 1st week of the study</td>
<td>Composite event: all-cause mortality and non-vascular access-related hospitalization at 6 months</td>
<td>• Rise in pre- to post-HD systolic BP was associated with ↑ odds of the composite outcome</td>
</tr>
<tr>
<td>Inrig et al. [53], 2009</td>
<td>1,748 (US)</td>
<td>• Intradialytic hypertension was not explicitly defined, but changes in systolic BP during HD measured as differences in post- and pre-HD systolic BP were assessed • Mean systolic BP values were computed from 3 consecutive HD treatments occurring prior to study enrollment</td>
<td>2-year all-cause mortality</td>
<td>• Every 10 mm Hg rise in pre- to post-HD systolic BP was associated with a 12% ↑ in mortality risk</td>
</tr>
<tr>
<td>Yang et al. [65], 2012</td>
<td>115 (Taiwan)</td>
<td>• Intradialytic hypertension was not explicitly defined, but a mean rise in post-HD systolic BP &gt;5 mm Hg was assessed • Mean systolic BP values were computed from 25 consecutive HD treatments occurring over 2 months</td>
<td>4-year all-cause and cardiovascular mortality</td>
<td>• Mean pre- to post-HD BP rise of &gt;5 mm Hg was associated with the highest risk of both 4-year all-cause and cardiovascular mortality</td>
</tr>
</tbody>
</table>

The proposed pathophysiology underlying intradialytic hypertension is multifactorial and, as such, presents several targets for intervention. Potential interventions include those aimed at mitigating volume overload, sympathetic over-activity, RAAS activation and endothelial cell dysfunction. Other strategies include antihypertensive medication and dialysate composition changes. As chronic volume overload is linked to an array of adverse cardiovascular consequences in HD patients, the first-line approach for the treatment of intradialytic hypertension is likely judicious target weight reduction. Increased UF and careful target weight reduction have been shown to improve intradialytic hypertension [58]. Related, dietary salt intake should be restricted as a means to reduce IDWG. While these interventions will
not resolve intradialytic hypertension in all patients, BP improvement in some patients is to be expected. However, volume challenges may exacerbate intradialytic hypertension in some patients as some data suggest overactivation of the RAAS and sympathetic nervous system in response to UF and associated cardiac preload reduction [67].

For patients not responsive to volume challenge, medication regimens should be carefully reviewed. Withholding antihypertensives prior to dialysis is a common practice and should be reconsidered in patients with intradialytic hypertension. Highly dialyzable antihypertensive drugs should be avoided or dosed post dialysis. In addition, ESA dosage should be reduced as much as safely possible and subcutaneous administration considered. Second, pharmaceutical interventions such as adrenergic blockers may be effective among patients with chronic intradialytic hypertension. Beta-blockers with alpha-receptor activity, such as carvedilol, are non-dialyzable and have been shown to reduce intradialytic hypertension, likely via their pleiotropic effects on endothelial cells. In a prospective, 12-week, pilot crossover study of 25 HD patients with intradialytic hypertension, treatment with carvedilol 50 mg twice daily reduced post-HD BP, 44 hour ambulatory BP and frequency of intradialytic hypertension episodes. Modest improvements in endothelial cell dysfunction were also demonstrated [63]. UF-induced activation of the RAAS may also contribute to intradialytic hypertension, suggesting that ACE inhibitors or angiotensin receptor blockers may be effective [68]. As the majority of ACE inhibitors are dialyzable, angiotensin receptor blockers may be better choices for patients with intradialytic hypertension.

Finally, dialysate prescription alterations may reduce intradialytic hypertension. Positive sodium balance is associated with thirst, IDWG and subsequent volume-mediated hypertension as well as endothelial dysfunction and associated endothelin-1–nitric oxide imbalance. HD prescription strategies aimed at reduction of serum sodium and the dialysate-sodium serum gradient may be beneficial. This hypothesis was recently tested in a 3 week, 2-arm randomized, crossover study in which 16 HD patients with intradialytic hypertension were randomized to low versus high dialysate-sodium serum gradients. Low dialysate sodium concentrations (5 mEq/L below serum sodium) were associated with decreased mean BPs [64]. Finally, high dialysate calcium prescriptions should be avoided in patients without hypocalcemia as a means to limit intradialytic hypertension from calcium-enhanced cardiac contractility.

Intradialytic BP Variability

Epidemiology, Definitions and Outcome Associations

While both hypotension and hypertension are well-established risk factors for adverse outcomes, BP deviation from the expected course, termed BP variability, has recently come to light as a prognostic factor. The majority of BP variability studies in the general and HD populations have considered long-term, visit-to-visit BP variability, measured at clinical visits across days, weeks or months. In the general population, greater long-term BP variability is associated with stroke, heart disease and mortality [69]. Among HD patients, long-term BP variability is measured with pre-HD BPs on a HD treatment-to-treatment basis and is associated with cardiovascular morbidity and mortality [70, 71]. Recent data suggest that short-term BP variability, considered as intradialytic BP fluctuations, is a cardiovascular risk factor among HD patients [72]. While some BP fluctuations in response to changing physiologic conditions are to be expected during dialysis, marked deviation from the expected intradialytic BP course is associated with adverse outcomes and is relevant to this review.

Intradialytic BP variability refers to BP fluctuations that are independent of other BP phenomena occurring during dialysis. This important distinction prevents conflation of the prognostic significance of BP fluctuations during HD with that of other intradialytic BP abnormalities. When considering intradialytic BP fluctuations, BP variability must be independent of pre-HD systolic BP and the expected biphasic intradialytic BP decline. BP variability can be defined by several metrics including standard deviation, absolute real variability, residuals derived from linear models and others. Residuals derived from linear mixed models with a spline function have been used to describe intradialytic systolic BP variability as they capture fluctuations from the expected 2-slope intradialytic BP course. Patient and procedural factors associated with variability from this expected course include older age, heart failure, heart disease, diabetes, greater UF volume, more rapid UF rates and larger IDWG [73].

In a study of 6,393 prevalent HD patients using absolute regression residuals from a linear effects model with a 2-slope spline, Flythe et al. [72] demonstrated an association between greater intradialytic systolic BP variability and increased all-cause and cardiovascular mortalities. High BP variability (defined as an absolute systolic BP residual >8.7 mm Hg, the cohort median) was associated with a 32% higher hazard of death (p = 0.04) com-
pared to low BP variability. When BP variability was considered in quartiles, dose–response relationships between BP variability and all-cause (p = 0.001) and cardiovascular (p = 0.04) mortality was observed. While this study provides strong support for an association between increased intradialytic BP variability and mortality, it is the sole investigation on this topic.

**Pathophysiology and Management**

In general, the pathophysiology of BP variability is not well-defined, but there are several plausible mediators. Impaired endothelial function, heightened inflammation, increased vessel wall stress, baroreceptor dysfunction and enhanced sympathetic nervous system activity are all potential contributors to BP variability [74]. Among dialysis patients, HD treatment fluid and osmolar shifts promote random BP fluctuations. Stiff vasculature, reduced cardiac output, autonomic dysfunction and neurohormonal imbalance that are common among HD patients may amplify these fluctuations and engender vulnerability to hemodynamic changes. Thus, BP fluctuations may induce subclinical end-organ hypoperfusion and subject patients to alternating periods of tissue hypoxia and capillary shear stress.

Recommendations regarding management of intradialytic BP variability are non-existent due to 2 key limitations: (1) lack of a clinically accessible chairside measure and (2) absence of studies investigating effective intervention strategies. First, to adequately distinguish intradialytic BP variability from the expected temporal BP course during HD, complex analytical approaches must be employed. The existing BP variability metrics are not easily calculated and are appropriate for research, but not for clinical settings. Thus, clinicians have no way to objectively classify BP variability. Second, clinical outcomes data for intradialytic variability are limited to a single study. This evidence suggests that risk factors for short-term (intradialytic) and long-term (visit-to-visit) BP variability may differ. Shafi et al. [71] demonstrated that greater UF was associated with lesser long-term (visit-to-visit) BP variability, but Flythe et al. [73] reported that greater UF was associated with greater short-term (intradialytic) BP variability. These conflicting findings are not surprising given the differences in hemodynamic environments of the intra- and interdialytic periods. Prior to making recommendations about management of intradialytic BP variability, the relative importance of long-term (visit-to-visit) and short-term (intradialytic) BP variability among dialysis patients must be established, and investigations examining mitigation strategies such as changes in fluid removal practice or perhaps antihypertensive agent selection must be conducted. Until then, it is prudent to minimize large BP fluctuations during dialysis by carefully monitoring hemodynamics, volume status and medication effects.

**Conclusion**

Existing observational studies provide compelling data supporting associations between intradialytic BP phenomena including hypotension, hypertension and variability and clinical outcomes. Unfortunately, the evidence base for effective management strategies of these dynamic BP changes is weak overall. We lack prospective studies, including randomized trials, confirming optimal diagnostic criteria, evaluating BP thresholds for intervention, assessing the clinical benefit of different interven-

### Table 4. Knowledge gaps regarding intradialytic BP abnormalities

| Intradialytic hypotension and hypertension |
| Evidence-based definitions and thresholds for intervention |
| Objective volume status measures including roles of bioimpedance and blood volume monitoring |
| Efficacy of UF profiling and sequential UF + dialysis in preventing BP falls and rises |
| Identification of optimal dialysate-serum sodium gradient differentials |
| Development of evidence-based prevention protocols |
| Development of evidence-based treatment protocols |
| Prospective evaluations of pathophysiologic mechanisms to confirm cross-sectional study findings |

| Intradialytic BP variability |
| Evidence-based definition and thresholds for intervention |
| Clinically accessible measure and assessment tool |
| Effective mitigation strategies |
| Confirmation of observational study results in prospective patient cohorts |
tion strategies and comparing preventative strategies. Table 4 provides an overview of evidence gaps that provide fertile ground for future research.

Despite these evidence limitations and clinical uncertainties, numerous peridialytic and intradialytic BP measurements confront dialysis unit staff and clinicians during HD administration. Emerging data suggest that vigilance for hemodynamic fluctuations beyond those associated with overt symptoms is prudent, adding further nuance and complexity to chairside BP interpretation and management. To confront this challenge, providers must draw upon their longitudinal patient relationships, enriched by knowledge about historical BP trends, treatment tolerance, volume status, prescription medications and health status garnered from frequent, attentive patient visits during dialysis. Careful volume assessment through physical examination, interdialytic BP evaluation and HD treatment response, supplemented by data from blood volume monitors and bioimpedance, when available, is paramount. Until prospective studies elucidate the optimal management approaches to intradialytic hypertension, hypertension and variability, individualized prescriptions of antihypertensives, dialysate composition and fluid removal along with close hemodynamic monitoring are the most appropriate therapeutic approaches to limit harm from intradialytic BP fluctuations.

Disclosure Statement

Dr. J.E. Flythe has received speaking honorarium from Dialysis Clinic, Inc. Dr. M.M. Assimon has no related disclosures.

Funding

Dr. M.M. Assimon is supported by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health Grant T32 DK007750.


74 Rothwell PM: Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010;375:938–948.